Brand name: Ansimar

Generic name: Doxofylline

Drug Classification: Antiasthmatic & COPD Preparations
Indication: Bronchial asthma & pulmonary disease w/ spastic bronchial component.
Mechanism of action: Adrenergic bronchodilators and phosphodiesterase inhibitors both
work by increasing intracellular level of cyclic-3’,5’- adenosine monophosphate
(cAMP); adrenergics by increasing production and phosphodiesterase inhibitors
by decreasing breakdown. Increased levels of cAMP produce bronchodilation.
Corticosteroids act by decreasing airway inflammation. Anticholinergics
(ipratropium) produce brondhodilation by decreasing intracellular levels of
cyclic guanosine monophosphate (cGMP). Leukotriene receptor antagonists and
mast cell stabilizers decrease the release of substances that can contribute to
bronchospasm.
Dosage: Tab Adult 1 tab bid- tid. Syr Children >12 yr 10 mL once- tid, <12 yrs 6-9
mg/kg bid.
Contraindication: Acute MI, hypotension, lactation
Special Precaution: Liver disease, CHF, chronic obstructive lung disease, concomitant
infections. Pregnancy.
Adverse Reaction: Nausea, vomiting, epigastric pain, cephalalgia, irritability, insomnia,
tachycardia, extrasystole, tachypnea, hyperglycemia, albuminuria.
Form: Tablet- 400 mg; syrup- 100mg/5mL
Pregnancy Risk Category: (Not yet applicable)
Nursing Responsibilities:
 Assess lung sounds, pulse and blood pressure before administration and
during peak of medication. Not amount, color, and character of sputum
produced.
 Monitor pulmonary function tests before initiating therapy and periodically
during therapy to determine effectiveness of medication.
 Observe for paradoxical bronchospasm (wheezing). If conditions occur,
withhold medication and notify physician of other health care professional
immediately.